SG Americas Securities LLC Invests $1.05 Million in Grifols, S.A. $GRFS

SG Americas Securities LLC purchased a new position in Grifols, S.A. (NASDAQ:GRFS) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 112,138 shares of the biotechnology company’s stock, valued at approximately $1,048,000.

A number of other hedge funds have also recently made changes to their positions in GRFS. Bank of Montreal Can grew its holdings in shares of Grifols by 3,205.1% in the third quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock worth $30,017,000 after purchasing an additional 2,922,540 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Grifols by 383.7% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,800,645 shares of the biotechnology company’s stock worth $27,894,000 after purchasing an additional 2,221,633 shares during the last quarter. Capital World Investors grew its holdings in shares of Grifols by 5.9% in the third quarter. Capital World Investors now owns 22,926,140 shares of the biotechnology company’s stock worth $228,344,000 after purchasing an additional 1,273,391 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Grifols by 52.1% in the second quarter. Bank of America Corp DE now owns 3,017,675 shares of the biotechnology company’s stock worth $27,280,000 after purchasing an additional 1,034,229 shares during the last quarter. Finally, Barclays PLC lifted its stake in Grifols by 722.5% in the third quarter. Barclays PLC now owns 1,046,853 shares of the biotechnology company’s stock worth $10,427,000 after acquiring an additional 919,581 shares during the period.

Analyst Ratings Changes

A number of research firms recently weighed in on GRFS. Zacks Research raised shares of Grifols from a “strong sell” rating to a “hold” rating in a research note on Friday, February 6th. Wall Street Zen raised shares of Grifols from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Finally, Weiss Ratings lowered shares of Grifols from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Three analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Grifols presently has a consensus rating of “Reduce” and an average target price of $10.00.

Grifols Stock Up 3.6%

NASDAQ:GRFS opened at $8.39 on Thursday. Grifols, S.A. has a 1-year low of $6.19 and a 1-year high of $11.14. The company has a 50-day moving average of $8.63 and a 200 day moving average of $8.97. The firm has a market cap of $5.71 billion, a PE ratio of 44.16, a price-to-earnings-growth ratio of 0.29 and a beta of 0.70. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.51 and a quick ratio of 0.88.

Grifols (NASDAQ:GRFS) last released its quarterly earnings data on Saturday, February 14th. The biotechnology company reported $0.38 earnings per share for the quarter. Grifols had a net margin of 6.65% and a return on equity of 6.23%. The company had revenue of $2.32 billion during the quarter. As a group, research analysts anticipate that Grifols, S.A. will post 0.81 EPS for the current fiscal year.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.